REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
20/07/2026
Voltar para busca
Dado oficial do USPTO
MODAG
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
20/07/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 10, 42, 44
Data de depósito
31/01/2020
Data de registro
20/07/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
20/07/2021
Última transação
20/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
27
Localização do titular
DE
Examinador
CHUO, EMILY M
Unidade examinadora
L10
Localização atual
TMEG LAW OFFICE 101
Descrição da marca
The mark consists of the wording "MODAG" in a stylized font where the letters "M", "D", "A" and "G" are in dark blue, the letter "O" is grey, and the letters "O" and "G" encircle a green dot.
Titulares e representantes
Titulares
MODAG GmbH
Representantes
Catherine F. Hoffman Baker, Donelson, Bearman, Caldwell, & Berkowitz, PC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical substanceschemical materialschemical compositions and chemical preparationsall of the foregoing for use in science
Classe 5
Pharmaceutical drugs and medicines for the treatment of the nervous system and for the treatment of diseases characterized by pathological protein aggregation; diagnostic preparations for medical purposes
Classe 10
Medical apparatus and instruments for monitoring molecular biomarkers of neurodegenerative diseases and diseases characterized by pathological protein aggregation such as pathologically modified and/or pathologically aggregated proteins and parts and fittings therefor; Medical diagnostic apparatus for testing molecular biomarkers of neurodegenerative diseases and diseases characterized by pathological protein aggregation such as pathologically modified and/or pathologically aggregated proteins and parts and fittings therefor
Classe 42
Scientific and technological servicesresearch and design in the field of neurodegenerative diseases and diseases characterized by pathological protein aggregation; industrial analysis and research services in the field of neurodegenerative diseases and diseases characterized by pathological protein aggregation; biological research; research and development of new products for others; Conducting clinical trials for others in the field of nervous system diseases such as neurodegenerative diseases and diseases characterized by pathological protein aggregation; Scientific laboratory services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; testing of pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; development of pharmaceutical preparations and medicines; research and development of vaccines and medicines; pharmaceutical drug development services
Classe 44
Medical services in the field of diseases characterized by pathological protein aggregation; Medical diagnosis of nervous system diseases such as neurodegenerative diseases and diseases characterized by pathological protein aggregation; medical services in the field of neurodegenerative diseases; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis for the diagnosisprognosis and treatment of neurodegenerative diseases and diseases characterized by pathological protein aggregation; providing medical data and information in the field of nervous system diseases such as neurodegenerative diseases and diseases characterized by pathological protein aggregation to healthcare professionals; rental of medical apparatus and equipmentfittings therefor
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/10/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/02/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/02/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/02/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/02/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/02/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
19/12/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/12/2021
FIMP
FINAL DISPOSITION PROCESSED
01/12/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
20/10/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
20/07/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/05/2021
PUBO
PUBLISHED FOR OPPOSITION
04/05/2021
GPNX
NOTIFICATION PROCESSED BY IB
02/05/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
14/04/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
14/04/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/04/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
31/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
22/03/2021
RFNT
REFUSAL PROCESSED BY IB
19/10/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/09/2020
RFRR
REFUSAL PROCESSED BY MPU
25/09/2020
MAFR
APPLICATION FILING RECEIPT MAILED
25/08/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
22/08/2020
CNRT
NON-FINAL ACTION WRITTEN
21/08/2020
DOCK
ASSIGNED TO EXAMINER
21/08/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/08/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
20/08/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MODAG ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.